Des-gamma-carboxy prothrombin is a promising biomarker of hepatocellular carcinoma and a predictor of complications in patients with chronic liver diseases  

作　　者：Lan-Yue Pan Xiao-Meng Hu Peng Han Dao-Feng Yang 

机构地区：[1]Department and Institute of Infectious Diseases,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China [2]Tuberculosis Ⅳ Ward,Wuhan Pulmonary Hospital,Wuhan 430030,China [3]Department of Thoracic Surgery,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China

出　　处：《Hepatobiliary & Pancreatic Diseases International》2023年第2期200-204,共5页国际肝胆胰疾病杂志（英文版）

摘　　要：To the Editor: Although des-gamma-carboxy prothrombin(DCP) is considered a complementary biomarker to alpha-fetoprotein(AFP) in the diagnosis of hepatocellular carcinoma(HCC), its cut-off value has not been recommended in any guideline. This study aimed to explore the diagnostic efficacy of DCP on HCC.

关 键 词：PROTHROMBIN HEPATOCELLULAR diagnosis 

分 类 号：R735.7[医药卫生—肿瘤]